News

Beremagene geperpavec is the first FDA-approved treatment for DEB, a rare and burdensome disease.

A poster presentation from SCALE 2023 evaluated the use of ceramide-containing skin care products with prescription treatments for a healthy skin barrier.

A plethora of oral and topical treatments are available for patients, according to Stein Gold’s SCALE 2023 sessions.

Graber discusses isotretinoin dosing and monitoring pearls at SCALE 2023.

Catch up on coverage from the second day of SCALE 2023.

Cellulite treatments are not always as effective as patients may expect, according to Elizabeth Tanzi, MD, FAAD.

Click here to choose what topics you're excited to learn more about.

Julie Harper, MD, shared updated risks and benefits of using spironolactone and oral contraceptives to treat acne in women at SCALE 2023.

Results from the retrospective study were shared at SCALE 2023.

Among the dozens of sessions to be held at the Symposium for Cosmetic Advances and Laser Education (SCALE) 2023 Meeting in Nashville, Tennessee, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Catch up on coverage from the first day of SCALE 2023.

As co-director, Biesman is looking forward to all attendees being able to find medical and aesthetic sessions relevant to their education.

The Music City has no shortage of must-see destinations once sessions conclude each day at SCALE 2023.

Gold encourages all attendees to feel welcome as they attend both cosmetic and medical dermatology sessions.

The medical and cosmetic dermatology meeting begins today in Nashville, Tennessee.

In part 2 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

An ongoing study is evaluating the use of multimodal aesthetics protocol in treating patients with hair loss.

B244 demonstrated significant levels of efficacy in patients with mild-to-severe atopic dermatitis and itch.

Del Rosso previews his upcoming sessions at SCALE 2023 discussing the latest updates in management and treatment techniques.

New data from Dermavant showed high levels of efficacy and statistical significance for the topical cream, which is expected to have an sNDA on file with the US FDA in early 2024.

Click here to answer this week's poll.

Patients with chronic conditions like alopecia areata may experience a reciprocal relationship between their condition and mental health.

Pandya gives an in-depth overview of his vitiligo treatment pearls from the 2023 Pigmentary Disorders Exchange Symposium.

Previous research demonstrated the microdroplet injection’s ability to improve skin quality, smoothness, and overall hydration.

Researchers linked proximity to heavy traffic roadways and risk of atopic dermatitis.

Patients with atopic dermatitis were asked to rate the importance of several factors that may influence their decision to participate in a clinical trial.

ICYMI, this week we had stories about comorbidities in vitiligo, highlights from ACMS 2023, how to discuss sun protection with your patients, and more.

Christopher Bunick, MD, PhD, shares pearls from his research in benzene contamination in sunscreens and what advice he shares with patients.

Leading clinicians discuss sun protection best practices based on weather, climate, and travel needs.

Leading clinicians discuss sun protection and special issues in photosensitivity.